RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
214 hedge funds and large institutions have $3.21B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
4% more funds holding
Funds holding: 205 → 214 (+9)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Holders
214
Holding in Top 10
8
Calls
$92.8M
Puts
$73.6M
Top Buyers
| 1 | +$132M | |
| 2 | +$84.4M | |
| 3 | +$55M | |
| 4 |
Holocene Advisors
New York
|
+$37M |
| 5 |
Millennium Management
New York
|
+$34.9M |
Top Sellers
| 1 | -$153M | |
| 2 | -$66.3M | |
| 3 | -$33.7M | |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$31.6M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$31.1M |